Accutane Link To Depression Needs Further Study, FDA Committee Says
Executive Summary
Roche should use pharmacogenomic techniques to explore the potential link between Accutane and depression, FDA Dermatologic & Ophthalmic Drugs Advisory Committee consultant Robert Branch, MD, University of Pittsburgh Medical Center, suggested.
You may also be interested in...
FDA Approval Decisions Changing In Light Of Relabeling Failures - Woodcock
FDA is not approving some prescription drugs because of a lack of confidence in labeling restrictions to ensure appropriate prescribing behavior, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said during a National Public Radio interview Dec. 19.
FDA Approval Decisions Changing In Light Of Relabeling Failures - Woodcock
FDA is not approving some prescription drugs because of a lack of confidence in labeling restrictions to ensure appropriate prescribing behavior, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said during a National Public Radio interview Dec. 19.
FDA To Study "Labeling Fatigue": Do Serial Changes Influence Prescribing?
FDA is planning an internal research effort to examine the concept of "labeling fatigue," which suggests that serial label changes or extensive warnings in the package insert have limited ability to alter prescribing behavior.